News Search Results
Jul 03, 2025, 08:30 ET Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results
Company's industry influence. About Zhengye Biotechnology Holding Limited Through Jilin Zhengye Biological Products Co., Ltd., the Company's operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development,
More news about: Zhengye Biotechnology Holding Limited
Jul 03, 2025, 07:40 ET SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP
Jul 03, 2025, 07:30 ET INOVIO Announces Pricing of $25 Million Public Offering
Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Jul 02, 2025, 21:30 ET Probiotics in Animal Feed Market worth $8.27 billion by 2030- Exclusive Report by MarketsandMarkets™
overall well-being of animals, responding to both regulatory pressures and consumer demand for safer, more sustainable animal products. Advances in biotechnology have enabled the development of more effective, species-specific probiotic formulations, further driving their adoption across poultry, swine, cattle,
More news about: MarketsandMarkets
Jul 02, 2025, 21:09 ET 晶泰科技戰略投資MIT精英團隊Foundry Bio,生成式AI重塑萬億抗衰市場
RNA 引導系統、蛋白質工程和合成生物學技術。他做為第一作者的研發成就包括首個真核 RNA 引導 DNA 核酸酶、高靈敏度哺乳動物細胞狀態傳感器，以及同類最佳（best in class）的 AI 指導的少樣本蛋白工程模型；相關成果發表於《Nature》《Science》《Nature Biotechnology》《Nature Materials》等頂刊，促成六項國際專利並催生了三家初創公司。姜凱議目前在普林斯頓大學生物工程系擔任教職，是該系歷史上未經博士後訓練即受聘的最年輕教授，並擔任首位安進學者（「Amgen Science Fellow」），在 Howard
More news about: 晶泰科技
Jul 02, 2025, 19:34 ET Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Jul 02, 2025, 19:09 ET Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited
Jul 02, 2025, 19:00 ET Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
without patent extensions. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jul 02, 2025, 16:16 ET INOVIO Announces Proposed Public Offering
Pa., July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Jul 02, 2025, 16:15 ET Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public
More news about: Nektar Therapeutics
Jul 02, 2025, 10:15 ET Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancers Congress 2025
Mass., July 2, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy, today presented new clinical data from the ongoing STARt-001 Phase 1/2 trial of
More news about: Marengo Therapeutics
Jul 02, 2025, 10:12 ET Outlook 2030: Feed Phosphate Market to Surpass $3.22 Billion | Innovation in Animal Health & Precision Feeding Takes Center Stage | The Research Insights
growth to US$ 3.22 Billion by 2030, the Global Feed Phosphate Market represents a significant opportunity for biotechnology firms, startup nutrient solution providers, alternative mineral supplement developers, and market disruptors focusing on eco-friendly feed additives,
More news about: The Research Insights
Jul 02, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers - FTRE
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The Company claims to have the "scale and expertise to advise, design and deliver [its] customers' programs, projects
More news about: Pomerantz LLP
Jul 02, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Jul 02, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Jul 02, 2025, 09:07 ET X-Therma Showcases Groundbreaking Organ Preservation Technology at Johns Hopkins' "Hopkins on the Hill" Event
X-Therma Inc., a pioneering biotechnology company revolutionizing organ preservation and regenerative medicine, proudly announces its participation in the prestigious Hopkins on the Hill
More news about: X-Therma Inc.
Jul 02, 2025, 09:00 ET mAbxience Announces European Commission Approval of Denosumab Biosimilars
agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance
More news about: mAbxience
Jul 02, 2025, 09:00 ET mAbxience Announces European Commission Approval of Denosumab Biosimilars
agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance
More news about: mAbxience
Jul 02, 2025, 08:32 ET Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered
More news about: Curis, Inc.
Jul 02, 2025, 08:00 ET [iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
https://www.prnewswire.com/news-releases/intron-files-us-patent-for-three-novel-endolysin-based-drug-candidates-targeting-gram-negative-bacteria-302496380.html SOURCE iNtRON Biotechnology, Inc.
More news about: iNtRON Biotechnology, Inc.
Jul 02, 2025, 04:19 ET Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition
facilitated over $100 million in investment deals. About Arbele Arbele Limited is a clinical-stage biotechnology company developing potential first-in-class and best-in-class immunotherapies for digestive tract cancers. With strategic
More news about: Arbele
Jul 01, 2025, 13:55 ET ISS National Lab Partners with AIAA to Expand ASCEND with Low Earth Orbit-Focused Sessions in 2025 and 2026
25 years of continuous human presence on the ISS and the valuable research the space station has enabled, including advancements in biotechnology, fundamental science, and technology development. At ASCEND, research teams and programmatic leaders will discuss the critical impact of the
More news about: International Space Station National Lab
Jul 01, 2025, 11:52 ET Transformer Services Market Size to Surpass USD 8.23 billion by 2031, at a CAGR of 6.9%, Experiences Growth Due to Increasing Demand for Electricity Across | The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Jul 01, 2025, 11:23 ET Global Market for Media, Sera, and Reagents in Biotechnology to Reach $9.3 Billion by 2029
is driving advances in biotechnology, diagnostics, and targeted therapies. Technological advances: Rapid technological advances are transforming industries by enhancing efficiency, innovation, and automation. These breakthroughs drive progress in biotechnology, healthcare, and other sectors,
More news about: BCC Research LLC
Jul 01, 2025, 11:15 ET Smart Infrastructure Market Size Projected to Hit USD 2,745.9 Billion at an 18.3% CAGR by 2031
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners